AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A pharmaceutically administrable composition comprising inactivated cells of *Flavobacterium psychrophilum* cultivated from ~~in~~ a logarithmic growth phase culture and at least one pharmaceutically acceptable carrier or adjuvant.

2. (Currently Amended) A pharmaceutically administrable composition comprising components of inactivated cells of *Flavobacterium psychrophilum* cultivated from ~~in~~ a logarithmic growth phase culture and at least one pharmaceutically acceptable carrier or adjuvant, wherein said components comprises cell membrane components, vesicles, ~~and/or~~ and secretary products.

3. (Previously Presented) A method for preventing the cold-water disease in fish, comprising administering an effective dosage of the composition according to Claim 1 to a fish in need thereof to thus prevent cold-water disease.

4. (Canceled)

5. (Previously Presented) The composition according to Claim 1, wherein said *Flavobacterium psychrophilum* in a logarithmic growth phase are isolated from a growth culture by centrifugation or filtration.

6. (Previously Presented) The composition according to Claim 1, wherein said *Flavobacterium psychrophilum* in a logarithmic growth phase are inactivated by heat treatment.

7. (Previously Presented) The composition according to Claim 1, wherein said *Flavobacterium psychrophilum* in a logarithmic growth phase are inactivated by formalin treatment.

8. (Previously Presented) The composition according to Claim 1, wherein said pharmaceutically acceptable carrier is a liquid carrier.

9. (Previously Presented) The composition according to Claim 8, wherein said liquid carrier is water or physiological saline.

10. (Previously Presented) The composition according to Claim 1, wherein said pharmaceutically acceptable carrier is a solid carrier.

11. (Previously Presented) The composition according to Claim 10, wherein said solid carrier is talc or sucrose.

12. (Currently Amended) The composition according to Claim 2, wherein said components of inactivated cells of *Flavobacterium psychrophilum* cultivated from ~~in~~ a logarithmic growth phase culture are collected following ultrasonic pulverization of inactivated cells of *Flavobacterium psychrophilum*, which cells are isolated from a growth culture by centrifugation or filtration.

13. (Currently Amended) The composition according to Claim 2, wherein said

components of inactivated cells of *Flavobacterium psychrophilum* cultivated from a logarithmic growth phase culture are obtained from cells of *Flavobacterium psychrophilum* cultivated from ~~in~~ a logarithmic growth phase culture that have been ~~are~~ inactivated by heat treatment.

14. (Currently Amended) The composition according to Claim 2, wherein said components of inactivated cells of *Flavobacterium psychrophilum* cultivated from a logarithmic growth phase culture are obtained from cells of *Flavobacterium psychrophilum* cultivated from ~~in~~ a logarithmic growth phase culture that have been ~~are~~ inactivated by formalin treatment.

15. (Previously Presented) The composition according to Claim 2, wherein said pharmaceutically acceptable carrier is a liquid carrier.

16. (Previously Presented) The composition according to Claim 15, wherein said liquid carrier is water or physiological saline.

17. (Previously Presented) The composition according to Claim 2, wherein said pharmaceutically acceptable carrier is a solid carrier.

18. (Previously Presented) The composition according to Claim 17, wherein said solid carrier is talc or sucrose.

19. (Previously Presented) The method according to Claim 3, wherein said fish in

need thereof is an adult fish.

20. (Previously Presented) The method according to Claim 3, wherein said fish in need thereof is selected from the group consisting of ayu, crucian carp, salmon, yamame, rainbow trout, and silver trout.

21. (Previously Presented) The method according to Claim 3, wherein said effective dosage ranges from 1 mg to 5 g per 1 kg of body weight of said fish in need thereof.

22. (Previously Presented) The method according to Claim 3, wherein said administering is once to ten times per day.

23. (Previously Presented) The method according to Claim 3, wherein said administering is every day.

24. (Previously Presented) The method according to Claim 3, wherein said administering is at an interval of one or two days.

25. – 30. (Canceled)